Lamotrigine and valproate pharmacokinetics interactions in epileptic patients

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 2, 2009, Pages 93-99

  Lalic, Mladena ^a   Cvejic, Jelena ^a   Popovic, Jovan ^a   Bozic, Ksenija ^b   Golocorbin Kon, Svetlana ^a   Al Salami, Hani ^c   Mikov, Momir ^c,d  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b Clinical Centre of Vojvodina   (Serbia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d Department of Pharmacology Toxicology and Clinical Pharmacology ^*  (Serbia)

Author keywords

Lamotrigine; Pharmacokinetic interaction; Valproate

Indexed keywords

LAMOTRIGINE; VALPROIC ACID; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENTIATION; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MONOTHERAPY; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG INTERACTION; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTICONVULSANTS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; TRIAZINES; VALPROIC ACID; YOUNG ADULT;

EID: 68949110440     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191157     Document Type: Article

References (32)

1. Cohen A.F., Land CS., Breimer D.D., Yuen W.C., et al (1987): Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther., 42, 535-541.
2. Sweetman S (2007): Martindale: The complete drug reference. London, United Kingdom.
3. Green M.D., Bishop W.P., Tephley T.R.(1995): Expressed human UGT 1,4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab. Disp., 23, 299-302.
4. Thaddeus H.G., Fiedler-Kelly J., Cox E., et al (1999): Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J. Clin. Pharmacol., 39, 373-384.
5. Patasalos N.P., Froscher W., Pisani F., et al (2002). The importance of drug interactions in epilepsy therapy. Epilepsia, 43 (4), 365-385. (Pubitemid 34297175)
6. Binnie CD., Van Emde Boas W., Kasteleijn Nolste Trenite D.G., et al (1986). Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia, 27, 248-254 (Pubitemid 16065367)
7. Brodie M.J., Yuen A.W.C, and the 105 Study Group (1997): Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res., 26, 423-522
8. Ferrie C.D., Robinson R.O., Knott C., Panayiotopoulos C.P. (1995): Lamotrigine as an add-on drug in typical absance seizures. Act. Neurol. Scand., 91, 200-212
9. Ferrie C.D., Panayiotopoulos C.P. (1994) Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure, 3, 157-159
10. Patil K.M., Bodhankar S.L. (2005): Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. J. Pharmaceut. Biomed., 39, 181-186.
11. WHO. (1995): Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization.
12. WHO expert consultation. (2004): Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet, 157-163.
13. May T.W., Rambeck B., Jurgus U. (1996): Serum concentration of lamotrigine in epileptic patients: the influence of dose and co medication. Ther. Drug Monit., 18, 523-531.
14. Armijo J.A., Bravo J., Cuadrado A., et al. (1999): Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther. Drug. Monit., 21, 182-190.
15. Raymond G.M., Andrew B.B., Annie L.H., et al. (1998): Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of routine service. Br. Clin. Pharmacol., 46, 547-551.
16. Brodie M.J., Rochens A., Yuen A.W.C (1995): Doubleblind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet, 345, 476-479.
17. Gidal B.E., Sheth R., Parnell J., et al. (2003): Evaluation of VPA dose and concentration effect in lamotrigine pharmacokinetics: Implications for conversion to lamotrigine monotherapy. Epilepsy Res., 57, 85-93. (Pubitemid 38167725)
18. Gidal B.E., Anderson G.D., Rutecki P.R., et al. (2000): Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res., 42, 23-31.
19. Anderson G.D., Gidal B.E., Messenheimer J.A., et al. (2002): Time course of lamotrigine de-induction: impact step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res., 49, 211-217.
20. Batino D., Croci D., Granata T., Estienne M., et al. (1997): Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther. Drug Monit., 19, 620-627.
21. Bartoli A., Guerini R., Belmote A., et al. (1997): The influence of dosage, age, and co-medication on steady state plasma concentrations in epileptic children: a prospective study with preliminary assessment of correlation with clinical response. Ther. Drug Monit., 19, 252-260.
22. Green M.D., Bishop W.P., Theley T.R. (1995): Expressed human UGTI, 4-protein catalysis the formation of quaternary ammonium linked glucuronids. Drug Metab. Disp., 23, 299-302.
23. Philippe E.R., Penaloza A., Zahir S., et al. (2005): Carnitine in the treatment of valproic acid-induced toxicity- what is the evidence? Critical Care, 9, 431-440.
24. Gugker R., von Ubruh G.E. (1980): Clinical pharmacokinetic of valproic acid. Clin. Pharmacokinet., 10, 155-163.
25. Stefab H., Feuerstein T.J. (2007): Novel anticonvulsant drugs. Pharm. and Therapeutics, 113, 165-183.
26. Ptsalos N.P., Perucca E. (2003): Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet, 2, 347-355.
27. Baltes S., Fedrowitz M., Torlos C.L., et al. (2007): Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther., 320(1), 331-343.
28. Potschka H., Fedrowitz M., Loscher W.P. (2002): Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at blood brain barrier: evidence from mycrodialysis experiments in rats. Neurosci. Lett., 327, 173-176.
29. Yuen A.W.C, Land G., Weatherlely B.C., et al. (1992): Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Pharmacol., 33, 511-513.
30. Perucca E. (1999): The clinical pharmacokinetics of the new antiepileptic Drugs. Epilepsia, 40 (suppl. 9), S7-S13.
31. Schapel G., Black A., Lam E., et al. (1996): Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure, 5, 51-56. (Pubitemid 26116081)
32. Hussein Z., Posner J. (1997): Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br. J. Clin. Pharmacol., 43, 457-465.